Clinical trial
Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Who Progressed to First-line Platinum-Based Chemotherapy: APOLO TRIAL (LACOG 2425)
NCT07808359 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Who Progressed to First-line Platinum-Based Chemotherapy: APOLO TRIAL (LACOG 2425)
- Lead sponsor
- Latin American Cooperative Oncology Group
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- November 30, 2029
- Enrollment
- 58 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic penile squamous cell carcinoma, penile squamous cell carcinoma